| Secondary |
| Product Used For Unknown Indication |
15.5% |
| Neoplasm Malignant |
9.5% |
| Schizophrenia |
9.1% |
| Anxiety |
9.0% |
| Transient Ischaemic Attack |
9.0% |
| Depression |
8.0% |
| Bipolar Disorder |
5.7% |
| Breast Cancer |
4.0% |
| Antifungal Prophylaxis |
3.1% |
| Drug Use For Unknown Indication |
3.1% |
| Blood Pressure |
3.0% |
| Multiple Allergies |
2.8% |
| Myelodysplastic Syndrome |
2.8% |
| Acute Lymphocytic Leukaemia |
2.5% |
| Asthma |
2.4% |
| Peritoneal Dialysis |
2.3% |
| Blood Pressure Abnormal |
2.1% |
| Myeloid Leukaemia |
2.1% |
| Bladder Cancer |
2.0% |
| Hypertension |
2.0% |
|
| Weight Increased |
8.5% |
| Off Label Use |
7.6% |
| Vomiting |
6.8% |
| Neoplasm Malignant |
5.9% |
| Cerebral Haemorrhage |
5.1% |
| Dizziness |
5.1% |
| Drug Ineffective |
5.1% |
| Dyspnoea |
5.1% |
| Haematemesis |
5.1% |
| Hallucination, Visual |
5.1% |
| Headache |
5.1% |
| Intentional Drug Misuse |
5.1% |
| Malaise |
5.1% |
| Neutropenia |
4.2% |
| White Blood Cell Count Decreased |
4.2% |
| Atrial Fibrillation |
3.4% |
| Fatigue |
3.4% |
| Hyperbilirubinaemia |
3.4% |
| Rash |
3.4% |
| Thrombosis |
3.4% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.7% |
| Drug Use For Unknown Indication |
14.3% |
| Prophylaxis |
10.3% |
| Breast Cancer |
8.3% |
| Multiple Sclerosis |
4.4% |
| Hypertension |
4.1% |
| Acute Lymphocytic Leukaemia |
3.8% |
| Depression |
3.6% |
| Neoplasm Malignant |
3.5% |
| Hiv Infection |
3.5% |
| Chronic Obstructive Pulmonary Disease |
3.4% |
| Prophylaxis Of Nausea And Vomiting |
3.3% |
| Lung Neoplasm Malignant |
3.2% |
| Cough |
2.8% |
| Pain |
2.8% |
| Dehydration |
2.6% |
| Premedication |
2.4% |
| Nausea |
2.3% |
| Fluid Replacement |
2.0% |
| Medication Dilution |
2.0% |
|
| Vomiting |
12.9% |
| Death |
7.7% |
| Pyrexia |
6.5% |
| Weight Decreased |
6.5% |
| Drug Ineffective |
6.0% |
| Progressive Multifocal Leukoencephalopathy |
6.0% |
| Disease Progression |
4.8% |
| Dizziness |
4.4% |
| Lung Neoplasm Malignant |
4.4% |
| Rash |
4.4% |
| White Blood Cell Count Decreased |
4.4% |
| Product Quality Issue |
4.0% |
| Thrombocytopenia |
4.0% |
| Diarrhoea |
3.6% |
| Transient Ischaemic Attack |
3.6% |
| Vision Blurred |
3.6% |
| Off Label Use |
3.2% |
| Pain In Extremity |
3.2% |
| Pneumonia |
3.2% |
| Weight Increased |
3.2% |
|
| Interacting |
| Breast Cancer |
20.0% |
| Drug Use For Unknown Indication |
20.0% |
| Leukaemia |
20.0% |
| Product Used For Unknown Indication |
20.0% |
| Schizophrenia |
20.0% |
|
| Drug Interaction |
40.0% |
| Neoplasm Malignant |
20.0% |
| Osteoarthritis |
20.0% |
| Red Blood Cell Count Decreased |
20.0% |
|
